Dexcom, Inc. is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. These systems are used by patients, caregivers, and clinicians for diabetes management. The company's core business model revolves around its proprietary CGM technology, which includes sensors, transmitters, and software. Dexcom's primary revenue streams are derived from the sale of its disposable sensors and reusable transmitters and receivers. The company's market position is as a leader in the CGM market, with competitive advantages in its technology platform and strong brand recognition. Dexcom has a global presence, with key markets in North America, Europe, and Asia Pacific. The competitive landscape includes other medical device companies, as well as companies developing new technologies for glucose monitoring.

• Employees: 9,600 (as of December 31, 2023)
• Geographic Footprint: Operations in North America, Europe, Asia Pacific, Africa, and the Middle East
• Headquarters: San Diego, CA
• Founded: 1999
• Number of locations/facilities: Multiple manufacturing and office facilities globally
• Revenue: $3.62 billion (FY2023)
• Market Capitalization: Approximately $49.4 billion (as of June 30, 2023)
• Key Subsidiaries/Brands: Dexcom Clarity, Dexcom One, Dexcom Stelo

• CEO: Kevin R. Sayer
• CFO: Jereme M. Sylvain
• Chief Technology Officer: Girish Naganathan
• Other Key Executives: Matthew Dolan (Executive Vice President, Strategy, Corporate Development and Dexcom Labs), Paul Flynn (Executive Vice President, Global Revenue), Steven R. Pacelli (Executive Vice President and Managing Director, Dexcom Ventures), Barry J. Regan (Executive Vice President, Global Operations), Sadie M. Stern (Executive Vice President, Chief Human Resources Officer)

Key leaders have extensive experience in medical technology, finance, and operations.

• Annual Revenue: $3.62 billion (FY2023)
• Net Income: $541.5 million (FY2023)
• Market Cap: $49.4 billion (as of June 30, 2023)
• Total Assets: $6.26 billion (as of December 31, 2023)
• Number of employees: 9,600 (as of December 31, 2023)
• Key Financial Highlights: Revenue up 24% year-over-year, net income up 59% year-over-year (FY2023)

Dexcom offers several CGM systems and related products:

• Dexcom G6: An integrated CGM system that provides continuous glucose readings and is compatible with mobile devices and wearable technology.
• Dexcom G7: A next-generation CGM system with an all-in-one wearable sensor and transmitter, faster warm-up, and improved accuracy.
• Dexcom G6 Pro: A professional CGM system for healthcare providers to use with their patients.
• Dexcom Share: A remote monitoring system that allows users to share glucose data with designated recipients.
• Dexcom Real-Time API: A software component that enables third-party developers to integrate CGM data into their apps and devices.
• Dexcom ONE: A CGM system launched in Europe with similar features to the G6.
• Dexcom Stelo: A CGM product designed specifically for people with type 2 diabetes who do not use insulin and are not at risk for hypoglycemia.

Dexcom operates as a single reportable segment. The company's revenue is disaggregated by geographic region and sales channel:

• United States: $2.63 billion (72% of total revenue)
• International: $997.0 million (28% of total revenue)
• Distributor: $3.10 billion (85% of total revenue)
• Direct: $526.7 million (15% of total revenue)

Dexcom's strategy focuses on maintaining its technology platform leadership in CGM and leveraging its development expertise to bring new products to market rapidly. Key strategic initiatives include:

• Supporting the use of ambulatory products through direct sales and key distribution arrangements.
• Seeking broad coverage policies and reimbursement for its products.
• Providing a cloud-based data repository platform for data analysis and sharing.
• Expanding use of products to other patient care settings and demographics.
• Maintaining a high level of customer support and education.
• Pursuing the highest safety and quality levels for products.
• Leveraging technology platform to integrate CGM with insulin delivery systems and other digital health platforms.
• Expanding into new markets and indications, including Type 2 diabetes and pre-diabetes.

Dexcom operates in the highly competitive glucose monitoring market. Key market trends affecting the business include:

• Increasing prevalence of diabetes globally.
• Growing adoption of continuous glucose monitoring technology.
• Technological advancements in CGM devices.
• Increasing integration of CGM with insulin delivery systems.
• Growing demand for digital health solutions.

Major competitors include Abbott Laboratories, Medtronic, Roche, LifeScan, and Ascensia Diabetes Care. Dexcom competes on product performance, cost, ease of use, and brand awareness. Market share information is not explicitly provided in the filing.

• Pricing and Reimbursement Risks: Decreasing prices for products and cost-containment efforts by third-party payors could reduce revenue.
• Product Development Risks: Research and development efforts may not result in commercially viable products or adequate profitability.
• Manufacturing and Supply Chain Risks: Insufficient manufacturing capacity, supply disruptions, and suboptimal quality from third-party suppliers could harm the business.
• Competitive Risks: Competition from large, well-established companies could make it difficult to compete effectively.
• Regulatory Risks: Failure to comply with applicable laws and regulations could result in penalties and exclusion from government programs.